Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age

NCT07071558 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Immunization

Interventions

BIOLOGICAL: RSV vaccine formulation 1 dose
BIOLOGICAL: RSV vaccine formulation 2 dose
BIOLOGICAL: RSV vaccine formulation 3 dose
BIOLOGICAL: RSV vaccine formulation 4 dose
BIOLOGICAL: RSV vaccine formulation 5 dose
BIOLOGICAL: RSV vaccine formulation 6 dose
BIOLOGICAL: RSV vaccine formulation 7 dose
BIOLOGICAL: RSV vaccine formulation 8 dose

Sponsor

Sanofi